Hinrichs Lab - Selected Publications

View Dr. Hinrichs’s Complete List of Published Work in MyBibliography

  1. Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-González JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS. Cooperative armoring of CAR and TCR T-cells by T cell-restricted IL-15 and IL-21 universally enhances solid tumor efficacy. Clin Cancer Res. 2023 Nov 1. doi: 10.1158/1078-0432.CCR-23-1872. Epub ahead of print. PMID: 37910044.
  2. Norberg SM, Hinrichs CS. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell. 2023;41(1):58-69. Epub 20221117. doi: 10.1016/j.ccell.2022.10.016. PubMed PMID: 36400016; PMCID: PMC9839504.
  3. Cornetta K, Yao J, House K, Duffy L, Adusumilli PS, Beyer R, Booth C, Brenner M, Curran K, Grilley B, Heslop H, Hinrichs CS, Kaplan RN, Kiem HP, Kochenderfer J, Kohn DB, Mailankody S, Norberg SM, O'Cearbhaill RE, Pappas J, Park J, Ramos C, Ribas A, Riviera I, Rosenberg SA, Sauter C, Shah N, Slovin SF, Thrasher A, Williams DA, Lin TY. Replication Competent Retrovirus Testing (Rcr) in the National Gene Vector Biorepository: No Evidence of Rcr in 1595 Post-Treatment Peripheral Blood Samples Obtained from 60 Clinical Trials. Mol Ther. 2022. Epub 20221213. doi: 10.1016/j.ymthe.2022.12.006. PubMed PMID: 36518078.
  4. Bai K, Norberg SM, Sievers C, Meyer T, Friedman J, Hinrichs C, Allen CT. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Head Neck. 2022;44(10):E31-E7. Epub 20220711. doi: 10.1002/hed.27144. PubMed PMID: 35815785.
  5. Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022;7(74):eabl3995. Epub 20220805. doi: 10.1126/sciimmunol.abl3995. PubMed PMID: 35930653.
  6. Davies JS, Karimipour F, Zhang L, Nagarsheth N, Norberg S, Serna C, Strauss J, Chiou S, Gulley JL, Hinrichs CS. Non-synergy of PD-1 blockade with T-cell therapy in solid tumors. J Immunother Cancer. 2022;10(7). doi: 10.1136/jitc-2022-004906. PubMed PMID: 35793866; PMCID: PMC9260838.
  7. Robbins Y, Friedman J, Clavijo PE, Sievers C, Bai K, Donahue RN, Schlom J, Sinkoe A, Hinrichs CS, Allen C, Abdul Sater H, Gulley JL, Norberg S. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. J Immunother Cancer. 2021;9(8). Epub 2021/09/01. doi: 10.1136/jitc-2021-003113. PubMed PMID: 34462327; PMCID: PMC8407210.
  8. Norberg SM, Hinrichs CS. Advances in Adoptive Cell Therapy for Head and Neck Cancer. Otolaryngol Clin North Am. 2021;54(4):761-8. Epub 20210609. doi: 10.1016/j.otc.2021.05.001. PubMed PMID: 34116844.
  9. Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanovic S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021;27(3):419-25. Epub 20210208. doi: 10.1038/s41591-020-01225-1. PubMed PMID: 33558725.
  10. Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol. 2019;37(30):2759-68. Epub 20190813. doi: 10.1200/JCO.18.02424. PubMed PMID: 31408414; PMCID: PMC6800280.
  11. Marcinkowski B, Stevanovic S, Helman SR, Norberg SM, Serna C, Jin B, Gkitsas N, Kadakia T, Warner A, Davis JL, Rooper L, Hinrichs CS. Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1. J Immunother Cancer. 2019;7(1):229. Epub 20190828. doi: 10.1186/s40425-019-0678-x. PubMed PMID: 31455429; PMCID: PMC6712783.
  12. Stevanovic S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res. 2019;25(5):1486-93. Epub 20181205. doi: 10.1158/1078-0432.CCR-18-2722. PubMed PMID: 30518633; PMCID: PMC6397671.
  13. Jin BY, Campbell TE, Draper LM, Stevanovic S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3(8). Epub 20180419. doi: 10.1172/jci.insight.99488. PubMed PMID: 29669936; PMCID: PMC5931134.
  14. Kang Z, Stevanovic S, Hinrichs CS, Cao L. Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. Clin Cancer Res. 2017;23(22):6856-62. Epub 20170912. doi: 10.1158/1078-0432.CCR-17-1553. PubMed PMID: 28899967; PMCID: PMC7885032.
  15. Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200-5. Epub 2017/04/15. doi: 10.1126/science.aak9510. PubMed PMID: 28408606; PMCID: PMC6295311.
  16. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543-50. Epub 20150330. doi: 10.1200/JCO.2014.58.9093. PubMed PMID: 25823737; PMCID: PMC4417725.
  17. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641-5. Epub 2014/05/09. doi: 10.1126/science.1251102. PubMed PMID: 24812403; PMCID: PMC6686185.
  18. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56-71. Epub 2013/12/18. doi: 10.1111/imr.12132. PubMed PMID: 24329789; PMCID: PMC3920180.